Multifocal brain involvement in a patient with hairy cell leukemia successfully treated with rituximab and cladribine.
نویسندگان
چکیده
Brain involvement, although rare, can occur in HCL.The combination of cladribine and rituximab is a highly effective treatment of HCL with brain involvement.
منابع مشابه
Synchronous or Metachronous Hairy Cell Leukemia and Chronic Lymphocytic Leukemia: A Case Series and Literature Review
INTRODUCTION Concurrent hairy cell leukemia (HCL) and chronic lymphocytic leukemia (CLL) is rare; management is inadequately described in the literature. METHODS Retrospective chart review and clinical follow-up. RESULTS Five patients are described. The first patient developed synchronous HCL and CLL and was treated with rituximab for 13 months with HCL in remission and stable CLL. The seco...
متن کاملCancer Therapy: Clinical Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia
Purpose: In contrast with the classic form, variant hairy cell leukemia (HCLv) responds poorly to singleagent purine analogs, expresses unmutated BRAF, has shorter overall survival, and lacks effective standard therapy. No treatment has achieved a high complete remission (CR) rate even in small series, and of 39 reported cases from six studies, overall response rate after cladribine was 44% wit...
متن کاملCladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
PURPOSE In contrast with the classic form, variant hairy cell leukemia (HCLv) responds poorly to single-agent purine analogs, expresses unmutated BRAF, has shorter overall survival, and lacks effective standard therapy. No treatment has achieved a high complete remission (CR) rate even in small series, and of 39 reported cases from six studies, overall response rate after cladribine was 44% wit...
متن کاملPhase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.
Hairy cell leukemia (HCL) is an indolent B-cell neoplasm, strongly expressing CD20. Despite initial very high response rates following cladribine, many patients (pts) ultimately relapse. Having relapsed after prior treatment with cladribine, 24 HCL pts (21 male, 3 female) with a median age of 53.5 years were treated with rituximab at 375 mg/m2 intravenously weekly for 4 weeks. Of the pts, 3 (13...
متن کاملCost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom.
OBJECTIVE This article assesses the cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia (HCL) in the United Kingdom. METHODS A systematic literature search for papers on HCL was performed using MEDLINE, EMBASE, Current Contents, NHS Economic Evaluation Database, and the Cochrane computerized database. Search terms were HCL plus 1 of the followin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Blood advances
دوره 1 14 شماره
صفحات -
تاریخ انتشار 2017